Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.

Learn More
Drug Development Services for Brain Tumors
  • Home
  • Drug Development Services for Brain Tumors
Online Inquiry

Drug Development Services for Brain Tumors

Drug Development Services for Brain Tumors

Brain tumors account for only 2% of the incidence of all types of tumors and the incidence ranking is not even in the top 10, but they have been the focus of scientists' efforts to overcome because they are difficult to diagnose and difficult to treat. Due to the existence of the blood-brain barrier, almost all large molecules and more than 98% of small molecules are unable to enter the brain parenchyma. Brain tumors lack precise targeted therapeutic agents, and therefore there is a great unmet clinical need.

We provide drug development services for brain tumors

Drug development in brain tumors is characterized by high risk compared to other therapeutic areas, but it also means that there is huge market potential in this area. Alfa Cytology provides drug development strategies for brain tumor treatment, including molecularly targeted therapies, immune checkpoint inhibitors. By type, they include small molecule drugs, immunotherapy drugs, targeted therapy drugs, antibody drugs, and exosomes. By phase, the services include basic research and preclinical research, covering cell analysis, tissue analysis, multi-omics analysis, sequencing and in vitro assays, model construction, and cell line development.

By Type

Brain tumor small molecule drug development services

We offer small-molecule drug development services for brain tumors. Our R&D team has outstanding expertise in small molecule drug discovery for brain tumors, including theoretical computationally oriented structure design, target binding kinetics, and oncology studies. In addition, we are actively pursuing strategies that combine immunotherapy and small-molecule targeted therapies for the treatment of brain tumors.

Brain tumor targeted therapeutic development services

Although treatment options for brain tumor patients remain very limited, the molecular targeting of brain tumors is very complex. However, as a leader in this field, we are not giving up on bringing more therapeutic pathways to our customers in the brain tumor field. In addition to small molecule drugs and immunotherapy, we are also deeply involved in the field of targeted therapies. We are ready to help you find specific genes as promising targets for molecularly targeted brain tumor therapy.

Antibody drug development services for brain tumors

Antibody-mediated immunotherapy is an important tool for the immunotherapy of brain tumors. We aim to provide our customers with antibody development services for brain tumors through our proven technology platform. To expand the audience for antibody drugs, we are actively conducting antibody drug miniaturization studies. We are trying to obtain Fab fragments, single-chain antibodies, bispecific antibodies, trivalent antibodies, and miniature antibodies by enzymatic digestion or genetic engineering.

Exosome development services for brain tumors

Exosomes readily cross the blood-brain barrier into and out of the central nervous system. Exosomes are not only a new biomarker assay, but also provide potential molecular therapeutic targets that hold promise as vehicles for anti-brain tumor drug delivery. We can detect specific sequence changes in DNA isolated from brain tumor patient samples to identify potential biomarkers. We are also developing exosomes as an interventional target for immunotherapy.

By Phase

Basic research services for brain tumors

Our services include brain tumor stem cell analysis, circulating tumor cell assays, rare cell analysis, cell microarrays, and quantitative DNA analysis of brain tumor cells. At the tissue level, we offer tissue microarrays as well as organoid and organ microarray services. Of course, we also have extensive experience in brain tumor-specific gene analysis, genomics, spatial transcriptomics, metabolomics, proteomics, imaging omics, genetic analysis, and gene microarrays.

Preclinical research services for brain tumors

The purpose of preclinical studies is to provide preliminary testing of drug safety issues. Sometimes, preclinical studies can also provide some relevant information about the efficacy of a drug and lay the foundation for human trials of the drug. We help you capture potential opportunities and make early and informed decisions to maximize the likelihood of successful clinical studies with our brain tumor in vitro assay services, model-building services, and cell line development services.

Although the incidence of brain tumors is significantly lower than that of other neoplasms, they are difficult to diagnose, difficult to treat, and extremely lethal. Early diagnosis and treatment can extend the survival time of patients, and Alfa Cytology is actively focusing on the combination of immunotherapy, radiotherapy, and molecularly targeted therapies that act on the tumor microenvironment to help our customers advance their brain tumor drug development process as early as possible. Please feel free to contact to submit a request.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.